5-HT1A Inhibitors
2 drugsAbout 5-HT1A
The 5-HT1A receptor is a G protein-coupled receptor (GPCR) that modulates serotonergic neurotransmission in the central nervous system (CNS). It plays a crucial role in mood regulation and anxiety.
The 5-HT1A receptor is a drug target for various CNS disorders; however, there is currently no genetic evidence directly linking it to specific diseases.
Two FDA-approved drugs target 5-HT1A, including VIIBRYD (vilazodone hydrochloride). Both drugs are small molecules and are indicated for CNS conditions.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Untreated Follicular Lymphoma with only 1 trials.
Top Drugs
The competitive landscape includes two companies with approved drugs: Alembic and AbbVie.
Low market concentration suggests relatively low barriers to entry for new competitors.
Drug Modality Landscape
Modalities
Routes of Administration
5-HT1A is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore opportunities for novel modalities like antibodies or biologics to differentiate from existing therapies.
Clinical Trials 40 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 11 | 10 | 0 | 1 | 100% |
| Phase 2 | 8 | 4 | 0 | 4 | 100% |
| Phase 3 | 11 | 10 | 0 | 1 | 100% |
| Phase 4 | 10 | 7 | 3 | 0 | 70% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2011 - 2024)
Major Depressive Disorder
The first drug was approved in 2011, and the most recent in 2019, spanning a 9-year period.
The recent approval suggests continued interest, but a longer gap may indicate market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: Moderate (9 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 11 clinical trials targeting 5-HT1A.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities